KJ-Pyr-9 is a novel small-molecule inhibitor of c-Myc (Kd=6.5 ± 1.0 nM).

KL001 (KL-001) is a small molecule that specifically interacts with cryptochrome (CRY) and small molecule modulator of the circadian clock.

SEC inhibitor KL-2 is a peptidomimetic inhibitor of super elongation complex (SEC) and transcription elongation by Pol II, disrupts cyclin T1-AFF4 interaction (Ki=1.50 uM) within SEC; disrupts the interaction between the SEC scaffolding protein AFF4 and P

KN-92 is an inactive derivative of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

Ko 143 is a potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC90 = 26 nM), Ko 143 displays > 200-fold selectivity over P-gp and MRP-1 transporters.

Kojic acid is a natural substance produced by Aspergillus oryzae, also used as an anti-oxidant and radio-protective agent.

KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials.

KP372-1 is a specific Akt inhibitor that blocks proliferation and induces apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro.

KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and 5050s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MM

KPT-185 is an orally bioavailable selective inhibitor of CRM1 amd displayes potent antiproliferative properties at submicromolar concentrations,induced apoptosis (average 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines a

KPT-276, analog of KPT-185, is an orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of CRM1.

KR-32570 is a potent sodium hydrogen exchanger NHE1 inhibitor with IC50 of 50 nM.

KR-33028 is a potent, highly selective NHE1 inhibitor with IC50 of 2.59 uM.

KR-62436 (KR62436) is a potent, selective DPP4 inhibitor with IC50 of 0.78, 0.49, 0.14 uM for rat plasma, porcine kidney, human DPP4 (Caco-2), respectively.

KRAS G12C inhibitor 11 is a potent, selective, covalent and irreversible inhibitor of KRAS G12C, inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 5 nM.

KRAS inhibitor 11 is a first-in-class, high-affinity, noncovalent allosteric KRAS inhibitor, disrupts KRAS-Raf interaction with Kd of 1.2 uM.

KRAS inhibitor C6ME is a small-molecule compound that blocks biochemical and cellular functions of KRASG12V in vitro..

KRAS inhibitor Cmpd2 is a small-molecule compound that blocks biochemical and cellular functions of KRASG12V with IC50 of 0.8 uM in vitro.

K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C).

K-Ras(G12C) inhibitor 6 is an allosteric, and selective inhibitor of oncogenic K-Ras(G12C).

KRAS4b-PDEδ stablizer C19 is a small molecule that binds and stablizes the KRAS4b-PDEδ complex, decreases the viability and proliferation of colorectal cancer cells.

KRAS-G12C inhibitor 13 is a potnt, irreversible, covalent and in vivo-active inhibitor of KRAS-G12C, suppresses ERK phosphorylation with IC50 of 70 nM in H358 cell assays.